Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Sep 19;38(1):235.
doi: 10.1007/s00384-023-04530-6.

The benefits of adjuvant chemotherapy are associated with the kind of neoadjuvant therapy in stage ypI rectal cancer: evidence based on population analysis

Hualin Liao  1   2 , Tao Li  1   2 , Yahang Liang  1   2 , Yaxiong Liu  1   2 , Yuli Yuan  1   2 , Mingming Li  1   2 , Aidi Li  1   2 , Yang Liu  1   2 , Yao Yao  1   2 , Taiyuan Li  3   4
Affiliations

The benefits of adjuvant chemotherapy are associated with the kind of neoadjuvant therapy in stage ypI rectal cancer: evidence based on population analysis

Hualin Liao et al. Int J Colorectal Dis. .

Abstract

Purpose: The oncological role of adjuvant chemotherapy (ACT) remains debated in locally advanced rectal cancer (RC) after neoadjuvant therapy (NAT), especially ypI RC. In this study, we used population-based data to evaluate the benefits of ACT in stage ypI RC after NAT and surgery. Moreover, we tried to differentiate what kind of NAT (radiotherapy alone or chemoradiotherapy) was administered because this may affect the further efficacy of ACT.

Methods: All patients with stage ypI primary rectal malignancy were diagnosed in the SEER database between 2004 and 2017. The Kaplan-Meier method was applied to estimate the effects of ACT in survival analysis. Cox regression was performed to calculate the hazard ratio (HR) and the prognosis factors of survival. Propensity score matching (PSM) was used to balance the parameters between therapy groups.

Results: The overall cohort's median follow-up time was 105 months. For 5-year OS and CSS, there were no significant differences between the ACT ( +) and ACT (-) groups (p = 0.105; p = 0.788). However, subgroup analyses according to the kind of NAT found that ACT improved overall survival (OS) and cancer-specific survival (CSS) in patients who received neoadjuvant radiotherapy (nRT) (p < 0.001, p = 0.015). Among patients who received neoadjuvant chemoradiotherapy (nCRT), no significant survival benefits were found between the ACT ( +) and ACT (-) groups (p = 0.526, p = 0.288).

Conclusion: Our population-based cohort study suggested that the efficacy of ACT was associated with the kind of NAT. The ACT provides survival benefits in stage ypI RC for patients who received nRT. However, among patients who received nCRT, ACT did not improve long-term survival.

Keywords: Adjuvant chemotherapy; Neoadjuvant therapy; Rectal cancer; Survival, Stage ypI.

PubMed Disclaimer

References

    1. Sung H, Ferlay J, Siegel RL et al (2021) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71(3):209–249 - DOI - PubMed
    1. Benson AB, Venook AP, Al-Hawary MM et al (2018) Rectal Cancer, Version 2.2018, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw 16(7):874–901
    1. Keller DS, Berho M, Perez RO, Wexner SD, Chand M (2020) The multidisciplinary management of rectal cancer. Nat Rev Gastroenterol Hepatol 17(7):414–429 - DOI - PubMed
    1. Van Gijn W, Marijnen CaM, Nagtegaal ID et al (2011) Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer: 12-year follow-up of the multicentre, randomised controlled TME trial. Lancet Oncol 12(6):575–582
    1. Bregni G, Akin Telli T, Camera S et al (2020) Adjuvant chemotherapy for rectal cancer: current evidence and recommendations for clinical practice. Cancer Treat Rev 83:101948 - DOI - PubMed

LinkOut - more resources